We provide insights to supplement the current
expert consensus on Timber Pharmaceuticals. Our innovative recommendation engine employs a multidimensional algorithm to assess the company's growth potential using all available technical and fundamental data. The company's price-to-book ratio stands at 0.62. Generally, companies with similar Price to Book (P/B) ratios are known to outperform the market over the long term. Timber Pharmaceuticals reported a loss per share of
8.29. The company's last dividend was issued on May 19, 2020. The company underwent a
1:50 split on November 9, 2022.
Deep-dive analysis
Timber Pharmaceuticals, a clinical-stage biopharmaceutical company, presents an enticing investment opportunity in the midst of current market volatility. Despite its high Coefficient of Variation at
784.15, the company's promising pipeline, particularly its lead product candidate TMB-001, demonstrates potential for significant upside. With a Potential Upside of
15.25, the stock could provide substantial returns for investors willing to take on the associated risk. Moreover, the company's Information Ratio of
0.125 indicates that it has been able to generate a decent amount of return relative to the risk it has taken on with its investments. Despite the stock's recent Price Change of a loss of 0.05, the company's solid
fundamentals and promising pipeline could drive its stock price higher in the future. Furthermore, Timber Pharmaceuticals' Accumulation Distribution of
8.4K suggests that the stock is being accumulated rather than distributed, indicating that investors are buying up the stock. With the biotechnology industry on the rise, Timber Pharmaceuticals could offer a promising investment opportunity for those looking to capitalize on market volatility.
The successful prediction of Timber Pharmaceuticals
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Timber Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Timber Pharmaceuticals based on Timber Pharmaceuticals hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Timber Pharmaceuticals's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Timber Pharmaceuticals's related companies.
Use Technical Analysis to project Timber expected Price
Timber Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, delisted stock market cycles, or different charting patterns.
A focus of Timber Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Timber Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Breaking down Timber Pharmaceuticals Further
The company reported the previous year's revenue of 83.18
K. Net Loss for the year was (19.38
M) with loss before overhead, payroll, taxes, and interest of (5.26
M).
| 2019 | 2021 | 2022 | 2023 (projected) |
Revenues USD | 453.81 K | 886.53 K | 83.18 K | 85.37 K | Revenues | 453.81 K | 886.53 K | 83.18 K | 85.37 K |
Cost of Revenue Breakdown
Timber Pharmaceuticals Cost of Revenue yearly trend continues to be relatively stable with very little volatility. Cost of Revenue is likely to grow to about 76.7
K this year. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Where this item is not contained on the company consolidated financial statements and cannot otherwise be imputed the value of 0 is used. Timber Pharmaceuticals Cost of Revenue is relatively stable at the moment as compared to the past year. Timber Pharmaceuticals reported last year Cost of Revenue of 74,700
| 2010 | 237,000 |
| 2016 | 516,000 |
| 2017 | 250,000 |
| 2018 | 83,000 |
| 2022 | 74,700 |
| 2023 | 76,665.79 |
Timber Pharmaceuticals, a clinical-stage biopharmaceutical company, is emerging as a promising investment opportunity amidst market volatility. With a market capitalization of
9.51M and a total asset of 10.28M, Timber Pharmaceuticals is a small yet promising player in the healthcare and biotechnology sector. The company's debt to equity ratio is remarkably low at 0.06%, indicating a strong
financial position with minimal total debt of 331.15K. Despite a negative return on asset of 1.37 and return on equity of 3.43, the company's potential upside of 15.25 and a target price of 11 offer a promising outlook. Furthermore, the company's current ratio of 2.45X indicates a healthy short-term liquidity position, and its cash per share ratio of 3.78X further strengthens its financial stability. The company's shares are largely held by insiders and institutions, with 1.11% and 7.78% respectively, indicating a strong belief in the company's potential. However, the stock has a beta of -0.4, suggesting it may move in the opposite direction of the market, and a standard deviation of 15.09, indicating a high level of volatility. In conclusion, while Timber Pharmaceuticals carries certain risks, its strong financial position and potential upside make it a promising investment opportunity in the current volatile market. Investors should consider the company's
financial health, market position, and potential growth before making an investment decision.
Is Timber showing record of lower volatility?
The skewness level of Timber Pharmaceuticals has recently decreased to 5.95, indicating a potential reduction in volatility. This suggests that the stock's returns might be becoming more normally distributed, potentially reducing the risk for investors. Therefore, this emerging pattern could signify a transition towards a more stable period for Timber Pharmaceuticals, which could be attractive to investors seeking a less volatile investment within the pharmaceutical sector. Timber Pharmaceuticals is demonstrating above-average volatility over the chosen time frame. Investors should independently examine Timber Pharmaceuticals to ensure that their intended
market timing strategies align with their expectations about the company's volatility. Understanding various
market volatility trends often assists investors in timing the market. The correct use of volatility indicators allows traders to gauge the risk of Timber Pharmaceuticals' stock against market volatility during both bullish and bearish trends. The heightened level of volatility that accompanies bear markets can directly affect
Timber Pharmaceuticals' stock price, adding stress to investors as they watch the value of their shares plummet.
This usually compels investors to rebalance their portfolios by purchasing different stocks as prices drop. Despite a slight slump of 1 percent, Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, continues to show promise in the market. The company's focus on the development and commercialization of treatments for orphan dermatologic diseases, including its lead product candidate TMB-001, positions it well in a niche market. The company's valuation real value stands at
4.79, with a market value of
3.03, indicating potential for growth. The single analyst covering the stock has a strong buy recommendation with a target price of 11, which is significantly higher than the current trading price. This suggests a strong upside potential. As the fiscal year end approaches in December, investors should keep a close eye on Timber Pharmaceuticals. Despite the recent slump, the company's strong
fundamentals and the analyst's strong buy consensus could provide an attractive investment opportunity. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Timber Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
